|CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist|
RC Kevin, L Anderson, IS McGregor, R Boyd, JJ Manning, M Glass, ...
Frontiers in pharmacology 10, 595, 2019
|Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA|
DB Finlay, JJ Manning, MS Ibsen, CE Macdonald, M Patel, JA Javitch, ...
ACS chemical neuroscience 10 (10), 4350-4360, 2019
|Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists|
M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ...
Biochemical pharmacology 175, 113871, 2020
|The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F‐PY‐PICA, 5F‐PY‐PINACA, and their analogs|
SD Banister, RC Kevin, L Martin, A Adams, C Macdonald, JJ Manning, ...
Drug testing and analysis 11 (7), 976-989, 2019
|Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1, 8-naphthyridin-2-(1 H)-one-3-carboxamide scaffold|
AG Cooper, CRM Oyagawa, JJ Manning, S Singh, S Hook, NL Grimsey, ...
MedChemComm 9 (12), 2055-2067, 2018
|Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA|
A Ametovski, C Macdonald, JJ Manning, SAS Haneef, M Santiago, ...
ACS Chemical Neuroscience 11 (21), 3672-3682, 2020
|Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias|
JJ Manning, HM Green, M Glass, DB Finlay
Neuropharmacology 193, 108611, 2021